$SYK (Stryker Corporation)

$SYK {{ '2016-07-22T06:21:06+0000' | timeago}} • Webcast

Medical technologies firm $SYK reported 2Q16 organic sales growth of 6.6%, helped by growth in MedSurg and Neurotechnology segments. Organic growth in US was up 9% while sales outside the US were up 2%, impacted by ongoing destocking challenges in China. Pricing was down 1.3% from 2Q15.

$SYK {{ '2018-01-09T17:21:37+0000' | timeago}} • Announcement

$SYK said that for 4Q17 its preliminary results are of net sales growth of 10% to $3.5Bil, while for FY17, its net sales grew 9.9% to $12.4Bil. Excluding the impact of foreign currency & acquisitions, net sales rose 8.1% and 7.1% in 4Q17 and FY17. For 2018, $SYK expects modest headwinds that will be manageable within its overall financial targets.

$SYK {{ '2017-12-12T14:28:46+0000' | timeago}} • Announcement

$SYK said Howard Cox Jr. has notified the company that he will not stand for re-election at Stryker's 2018 Annual Meeting, which is expected to be held on May 2, 2018. In light of Cox's immense contributions to the company, he will be named Director Emeritus.

$SYK {{ '2017-12-11T21:53:53+0000' | timeago}} • Announcement

$SYK said that the simplified public tender offer for the shares and BSAAR warrants of VEXIM has closed. $SYK, which already owned over 50% of the share capital and voting rights of VEXIM, acquired an additional 4.04MM shares during the offer period, as well as 226,520 BSAAR warrants that it has exercised for new shares of VEXIM.

$ENTL {{ '2017-12-08T17:39:22+0000' | timeago}} • Announcement

Rowley Law PLLC is investigating potential claims against $ENTL and its BoD for breach of fiduciary duty concerning the proposed acquisition of the company by $SYK. Stockholders will receive $24.00 in cash for each share of $ENTL that they hold. The transaction is valued at about $662MM.

$SYK {{ '2017-12-07T16:33:56+0000' | timeago}} • Announcement

$SYK agreed to buy $ENTL for $24 per share, or an equity value of about $662MM. The transaction is expected to be dilutive to $SYK's 2018 adjusted EPS by about $0.04 and accretive thereafter. Guggenheim Securities served as financial advisor and Skadden, Arps, Slate, Meagher & Flom LLP served as outside legal counsel for $SYK.

$SYK {{ '2017-12-07T14:25:00+0000' | timeago}} • Announcement

$SYK BoD declared a quarterly dividend of $0.47 per share payable on January 31, 2018 to shareholders of record on December 29, 2017. This  represents an increase of approx. 11% compared to the prior year and the previous quarter.

$SYK {{ '2017-10-27T11:50:44+0000' | timeago}} • Infographic

$SYK Stryker Corp. Earnings AlphaGraphic: Q3 2017 Highlights

$SYK {{ '2017-07-28T15:37:01+0000' | timeago}} • Announcement

$SYK, which is seeing a steady growth in the surgical booms market, reported a 6.1% jump in revenue to $3Bil for the second quarter of 2017.  Stryker’s revenue from Neurotechnology rose 13% to $352MM.

$SYK {{ '2017-07-28T15:36:41+0000' | timeago}} • Announcement

Surgical equipment manufacturer $SYK posted a 2.9% increase in net earnings to $391MM for the second quarter of 2017, compared to a year ago period. Organic net sales growth for 2017 is expected to be in the range of 6.5-7.0% and adjusted EPS to be in the range of $6.45-6.55.

$SYK {{ '2017-06-19T12:28:25+0000' | timeago}} • Announcement

$SYK agreed to buy $NVDQ. The transaction is expected to be dilutive to $SYK's 2017 adjusted EPS by $0.03-0.05. There is no change in $SYK's 2017 adjusted EPS forecast of $6.35-6.45. For 2018, this transaction is expected to be neutral to $SYK's earnings and accretive thereafter.

$SYK {{ '2017-06-19T12:26:47+0000' | timeago}} • Announcement

$SYK agreed to buy $NVDQ for $11.75 per share, or $701MM with a net purchase price of $654MM, reflecting net cash of about $47MM. The transaction is expected to close at the end of 3Q17.

$GE {{ '2017-06-14T12:04:29+0000' | timeago}} • Announcement

$GE's GE Additive and $SYK have entered a partnership agreement to support $SYK's growth in additive manufacturing. The agreement covers new additive machines, materials and services for $SYK's global supply chain operations.

$SYK {{ '2017-05-08T16:05:41+0000' | timeago}} • Announcement

$SYK said its subsidiary Howmedica Osteonics will move forward with the 2016 Settlement Program that provides for compensation to additional eligible U.S. patients who had surgery to replace their Rejuvenate Modular-Neck hip stem and/or ABG II Modular-Neck hip stem, known as a revision surgery, prior to Dec. 19, 2016.

$SYK {{ '2017-05-08T16:04:06+0000' | timeago}} • Announcement

$SYK said its subsidiary Howmedica Osteonics has informed the courts in the New Jersey Multicounty and Federal Multidistrict litigations that 95% of additional registered eligible patients have enrolled in the Settlement Program under the Master Settlement Agreement announced in December 2016.

$SYK {{ '2017-05-03T12:53:59+0000' | timeago}} • Announcement

$SYK's BoD declared a quarterly dividend of $0.425 per share, payable on July 31, 2017 to shareholders of record on June 30, 2017. This represents an increase of 12% versus the prior year and unchanged from the previous quarter.

$SYK {{ '2017-04-25T21:46:05+0000' | timeago}} • Webcast

$SYK said spine is an important part of its growth strategy. The company plans to launch a number of new products over the course of 2017 which are expected to accelerate growth. $SYK also plans to bring a couple of products back on the market and these are starting to take hold. $SYK expects the spine business to improve in 2017.

$SYK {{ '2017-04-25T21:30:27+0000' | timeago}} • Webcast

$SYK is positive on the pace of the MAKO system upgrades. The company started doing the upgrades in 4Q16 and they are continuing to accelerate sequentially. $SYK believes the vast majority of the robots in the field will get upgraded and this process will continue through 2018. The company expects these upgrades to continue to build.

$SYK {{ '2017-04-25T20:36:17+0000' | timeago}} • Announcement

For FY17, $SYK anticipates organic sales growth to be in the range of 5.5-6.5%. Adjusted net EPS is expected to be in the range of $6.35-6.45.

$SYK {{ '2017-04-25T20:32:41+0000' | timeago}} • Announcement

Medical technology company $SYK reported 10.4% increase in its 1Q17 earnings, helped by increased revenue growth. Net earnings rose to $444MM from $402MM during 1Q16. Diluted EPS rose 9.3% to $1.17 from $1.07 in prior year quarter. Net sales rose 18.4% YoY to $2.96Bil. Excluding items, $SYK earned $1.48 per share, up 19.4%.

$SYK {{ '2017-02-08T15:32:03+0000' | timeago}} • Announcement

$SYK BoD declared a quarterly dividend of $0.425 per share payable on April 28, 2017 to shareholders of record on March 31, 2017. This represents 12% increase versus the prior year.

Recent Transcripts

CMD (Cantel Medical Corp.)
Thursday, December 7 2017 - 4:00pm
MDT (Medtronic plc)
Tuesday, November 21 2017 - 1:00pm
SSYS (Stratasys Ltd.)
Tuesday, November 14 2017 - 1:30pm
TRXC (TransEnterix, Inc.)
Thursday, November 9 2017 - 9:30pm
CNCE (Concert Pharmaceuticals, Inc.)
Thursday, November 9 2017 - 1:30pm
GMED (Globus Medical, Inc.)
Wednesday, November 8 2017 - 10:30pm
PCRX (Pacira Pharmaceuticals, Inc.)
Wednesday, November 8 2017 - 1:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Wednesday, November 8 2017 - 1:30pm
CCXI (ChemoCentryx, Inc.)
Tuesday, November 7 2017 - 10:00pm
HAE (Haemonetics Corporation)
Tuesday, November 7 2017 - 1:00pm
PTLA (Portola Pharmaceuticals, Inc.)
Monday, November 6 2017 - 9:30pm
TXMD (TherapeuticsMD, Inc.)
Monday, November 6 2017 - 1:00pm
HRC (Hill-Rom Holdings, Inc.)
Friday, November 3 2017 - 12:00pm
TFX (Teleflex Incorporated)
Thursday, November 2 2017 - 12:00pm
SYN (Synthetic Biologics Inc.)
Wednesday, November 1 2017 - 8:30pm
WMGI (Wright Medical Group N.V.)
Wednesday, November 1 2017 - 8:30pm
STE (Steris Plc)
Wednesday, November 1 2017 - 2:00pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
CRY (CryoLife Inc.)
Tuesday, October 31 2017 - 12:00pm
RMD (ResMed Inc.)
Thursday, October 26 2017 - 8:30pm

AlphaGraphics you may like